$8.67
−0.57%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$8.85
From 52W high−88.11%
Volume62263.00
Market cap$148.31M
P/E (TTM)—
P/S (TTM)6.3x
Div yield—
Key dataNov 4, 2026
Open
$8.85
From 52W high
−88.11%
Volume
62263.00
Market cap
$148.31M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.2x
P/E (TTM)
—
RSI (14)
53.6
MomentumView details →
1D Return
−0.57%
YTD Return
−87.94%
SummaryUpdated Jun 1, 2026
Avidity Biosciences, Inc. (NASDAQ:RNA) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in San Diego, California. The company went public in June 2020 and specializes in developing a novel class of precision medicines called antibody oligonucleotide conjugates (AOCs) to treat rare genetic diseases, particularly those affecting muscle function. Avidity represents a pioneering approach in biotechnology by combining the targeting capabilities of antibodies with the therapeutic potential of oligonucleotides to address previously undruggable genetic conditions.
Similar companies
Latest newsMore news →
Atrium Therapeutics entered into a securities purchase agreement with institutional investors for a private placement expected to generate approximately $50 million in gross proceeds.27d agoNovartis AG reported that its experimental drug del-brax, acquired through the Avidity Biosciences deal, showed promise in an early to mid-stage study for facioscapulohumeral muscular dystrophy.134d agoNovartis acquired Avidity as part of a $12 billion takeover.146d ago